Study | NP/CRa | Populationa | N | NDI (T0) | GPE | Stable | SDC | MIC (sens/spec) |
---|---|---|---|---|---|---|---|---|
Cleland[9]b | NP | acute + chronic | 137 | 32.2-35.7 | 15 pt | -3 to +3 | 11.6* | 9.5 (0.83/0.72) |
Young[14]b | CR | average 4Â weeks | 165 | 24-25 | 13/15Â pt | -1 to +1 | 17.9* | 8,5 (0.62/0.79) |
Young[13] | NP | unclear | 91 | 15.8-18.0 | 15Â pt | -2 to +2 | 12.1* | 7.5 (n.r.) |
Cleland[9]b | NP | acute + chronic | 137 | 32.2-35.7 | 15 pt | -2 to +2 | 8.1 | 7.0 |
Cleland[8] | NP + CR | average 2 weeks | 38 | 21.9-20.7 | 15 pt | -3 to +3 | 12.0 | 7.0 (0.52/0.59) |
Young[14]b | CR | average 4Â weeks | 165 | 24-25 | 13/15Â pt | -2 to +2 | 15.9* | 6.5 (0.57/0.67) |
Jorritsma[15] | NP | chronic | 76 | 21 | 7Â pt | -1 to +1 | 8.4 | 3.5 |
Pool[10] | NP | acute + chronic | 183 | 14.5 | 6 pt | 2 to 4 | 10.5 | 3.5 (0.90/0.70) |
Vos[12]c | NP | acute | 187 | 13.0-16.0 | 7Â pt | 3 to 5 | 7.62 | n.r.a |
Trouli[11]d | NP | acute + chronic | 65 | n.r. | 15 pt | -3 to +3 | 3.03 | n.r.a |